Physician profile
Deepa C Lingam
NPI 1336246297
$5,495.72
in general payments reported to CMS, 2019-2025
29 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $57.57 · 2021: $130 · 2022: $892 · 2023: $1,571 · 2024: $1,448 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,074.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,312.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $832.21 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $573.24 | 2019-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $436.91 | 2023-2025 | Taltz, Olumiant, Zepbound |
| Journey Medical Corporation | $355.02 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $347.52 | 2020-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $249.18 | 2023-2024 | Vtama |
| Pfizer INC. | $247.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $148.12 | 2022-2025 | |
| Allergan, INC. | $147.23 | 2021-2022 | |
| Celgene Corporation | $128.80 | 2019-2023 | Sotyktu |
| Genzyme Corporation | $118.89 | 2023-2025 | |
| Incyte Corporation | $71.42 | 2022-2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.03 | 2024-2025 | Spevigo |
| Janssen Biotech, INC. | $63.82 | 2019-2024 | Tremfya, Simponi, Stelara |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $55.67 | 2023-2025 | Zoryve |
| Botanix Sb INC | $54.63 | 2025 | Sofdra |
| Leo Pharma INC. | $54.38 | 2025 | Adbry, Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.17 | 2019-2024 | Cabtreo |
| Genentech USA, INC. | $28.42 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $27.28 | 2020 | |
| Revance Therapeutics, INC. | $24.26 | 2025 | Daxxify |
| Ucb, INC. | $20.79 | 2025 | Bimzelx |
| Aclaris Therapeutics, INC. | $20.27 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.18 | 2025 | |
| Mayne Pharma Commercial LLC | $16.58 | 2025 | |
| Biofrontera INC. | $15.62 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $11.89 | 2022 | |
| Organon LLC | $7.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Lingam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.